Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002091 · ClinicalTrials.gov registry record · NA

An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

A NA study of HIV Infections, sponsored by Community Research Initiative of New England.

Completed
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT00002091: Completed NA study of HIV Infections, sponsored by Community Research Initiative of New England.

NCT00002091 is a NA study of HIV Infections that has completed, run by Community Research Initiative of New England. The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002091, a NA study of HIV Infections, has completed, sponsored by Community Research Initiative of New England.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

PRIMARY: To determine whether pentoxifylline changes the self-reported measures of quality of life status, using measures of scores from double-blinded drug withdrawal and drug restart periods. SECONDARY: To measure the changes in monthly CD4 counts, fasting serum triglyceride levels, and weight; to assess the safety of pentoxifylline in HIV-infected persons.

Conditions Studied

HIV Infections

Interventions

  • DRUG Pentoxifylline

Study Locations (1)

Massachusetts

  • CRI of New England - Brookline

Trial Details

FieldValue
Enrollment Target 60 participants
Phase NA
Community Research Initiative of New England

9 total trials

What the finished NCT00002091 record still lists

NCT00002091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Pentoxifylline is the first listed.

NCT00002091 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00002091 about?

NCT00002091 is a clinical study titled "An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent". PRIMARY: To determine whether pentoxifylline changes the self-reported measures of quality of life status, using measures of scores from double-blinded drug withdrawal and drug restart periods. SECONDARY: To measure the changes in monthly CD4 counts, fasting serum triglyceride levels, and weight; t...

What is the current status of trial NCT00002091?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants.

What conditions does trial NCT00002091 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002091?

The interventions under investigation include: Pentoxifylline (DRUG).

Who is sponsoring clinical trial NCT00002091?

This trial is sponsored by Community Research Initiative of New England, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002091 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002091's enrollment target sits among peer trials

60 322nd of 542 higher than 205 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Related registry views

Source: ClinicalTrials.gov NCT00002091, the US trial registry maintained by the National Library of Medicine. NCT00002091 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.